Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
Century Therapeutics (NASDAQ: IPSC) announced that Chad Cowan, Ph.D., Chief Scientific Officer, will present at Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025 at 12:20 p.m. ET in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) announced that Chad Cowan, Ph.D., Chief Scientific Officer, will present at Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025 at 12:20 p.m. ET in New York.
A live webcast of the presentation will be available on Century’s Investors page at www.centurytx.com, and an archived replay will be accessible for at least 30 days after the event.
Details
News Market Reaction – IPSC
On Oct 15, the first trading day after this news, IPSC closed 1.77% above the previous close.
Data tracked by StockTitan Argus for the Oct 15 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will present at Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025, at 12:20 p.m. ET in New York, NY.
A live webcast of the presentation will be available on the Investors page of Century’s website at www.centurytx.com. An archived replay will be available for at least 30 days.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is a clinical-stage biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases and cancer. The company’s therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.
For More Information:
Century Therapeutics
Douglas Carr
Senior Vice President, Finance
investor.relations@centurytx.com
JPA Health
Sarah McCabe
smccabe@jpa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.